CytomX Therapeutics, Inc. 4
4 · CytomX Therapeutics, Inc. · Filed Apr 17, 2017
Insider Transaction Report
Form 4
Kavanaugh William Michael
CSO, Head Res.&Non-Clin. Dev.
Transactions
- Award
Stock Option (Right to Buy)
2017-04-14+48,368→ 96,736 totalExercise: $4.47Exp: 2025-05-06→ Common Stock (48,368 underlying)
Footnotes (1)
- [F1]On May 7, 2015, the Reporting Person was granted an option to purchase 96,736 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On September 26, 2016, the first performance milestone was achieved resulting in 50% of the Performance Option vesting. On April 14, 2017, the second performance milestone was achieved resulting in the remaining 50% of the Performance Option vesting.